Login to Your Account



ASCO Genitourinary Cancer Symposium

Side Effects Data, Too, Impress for New Prostate Cancer Drugs

By Anette Breindl
Science Editor

Wednesday, February 1, 2012

Only two weeks after disappointing news on its Alzheimer's disease candidate, Dimebon (latrepirdine), Medivation Inc. had better news to share. Data from its Phase III AFFIRM trial of prostate cancer drug MDV3100, which will be presented later this week, were highlighted in a press conference put on by the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium Tuesday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription